Source comparison
MK-677 for IGF-1 Elevation Research: Clinical Evidence Comparison
MK-677 25mg Ghrelin receptor agonist 2–3× baseline 60–127% above baseline Yes. Maintains circadian rhythm Once daily Gold standard for sustained IGF-1 research. No tolerance development, oral administration, preserved endogenous secretion patterns GHRP-2 100mc
This comparison does not assign a generated winner or score.
- MK-677 25mg
- Ghrelin receptor agonist
- 2–3× baseline
- 60–127% above baseline
- Yes. Maintains circadian rhythm
- Once daily
- Gold standard for sustained IGF-1 research. No tolerance development, oral administration, preserved endogenous secretion patterns
- GHRP-2 100mcg
- Growth hormone releasing peptide
- 5–8× baseline (acute spike)
- 20–35% above baseline
- No. Blunts natural pulses
- 2–3× daily subcutaneous
- Strong acute response but rapid desensitization. IGF-1 elevation declines significantly after 4–6 weeks despite continued dosing
- CJC-1295 2mg weekly
- GHRH analogue with albumin binding
- 1.5–2× baseline (sustained)
- 40–60% above baseline
- Partially. Extends pulse duration
- Once weekly subcutaneous
- Moderate sustained response. Better than short-acting peptides but lower peak IGF-1 than MK-677, injection requirement limits compliance
- Exogenous rhGH 4 IU daily
- Direct GH replacement
- 10–15× baseline
- 80–150% above baseline
- No. Suppresses endogenous production
- Daily subcutaneous
- Highest acute IGF-1 but suppresses natural GH axis within 2–4 weeks. Not viable for long-term research protocols requiring intact feedback loops